查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951770

胎盘干细胞疗法治疗神经系统疾病市场分析及预测（至2035年）：按类型、产品、服务、技术、应用、最终用户、流程、阶段、解决方案和治疗方法

Placental Stem Cell Therapy for Neurological Disorders Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions, Mode
出版日期: | 出版商: Global Insight Services | 英文 326 Pages | 商品交期: 3-5个工作天内

价格
简介目录

用于治疗神经系统疾病的胎盘干细胞疗法市场预计将从2024年的4.423亿美元成长到2034年的23.259亿美元，复合年增长率约为31.7%。该市场涵盖利用胎盘组织来源的干细胞来治疗神经系统疾病。这种创新方法利用胎盘干细胞的再生能力来修復受损的神经组织并改善神经功能。推动市场成长的因素包括神经系统疾病盛行率的上升、干细胞研究的进步以及再生医学领域投资的增加。关键趋势包括个人化治疗、监管发展和策略研发合作。

受再生医学的进步和神经系统疾病盛行率不断上升的推动，胎盘干细胞治疗神经系统疾病市场预计将迎来显着增长。治疗应用领域是推动市场成长的主要动力，尤其是在阿兹海默症和帕金森氏症的治疗方面，已展现出令人鼓舞的成果。这些治疗方法在满足未被满足的医疗需求方面发挥关键作用。研究领域则受益于胎盘干细胞在神经发生和神经修復方面潜力的持续探索。临床试验和研究倡议的投资不断增加，也为该领域的成长提供了支持。在各个细分领域中，自体干细胞疗法因其免疫排斥风险较低且符合伦理考量，已成为表现最佳的疗法。异体移植疗法凭藉其可扩展性和可及性优势，位居第二，使其成为许多临床应用的理想选择。干细胞采集和处理技术的创新进一步提升了这些治疗方法的疗效和安全性，促进了其在医疗保健领域的广泛应用。

市场区隔
类型 同种异体、自体
产品 冷冻保存的胎盘干细胞，新鲜胎盘干细胞
服务 干细胞库、干细胞扩增、干细胞分化、咨询服务
科技 细胞培养技术、3D生物列印、微流体技术
目的 帕金森氏症、阿兹海默症、多发性硬化症、中风、脑性麻痹、脊髓损伤
最终用户 医院、专科诊所、研究机构、生物製药公司
流程 分离、增殖、分化和冷冻保存
步 临床前研究、临床试验与商业化
解决方案 治疗方案、诊断方案
治疗方法 侵入性、非侵入性

用于治疗神经系统疾病的胎盘干细胞疗法市场正经历市场份额、定价和产品创新方面的动态变化。该市场的特点是领先的生物技术公司之间竞争激烈，每家公司都透过策略性的产品发布来争夺市场主导地位。定价策略受到治疗方法的先进性和研发成本的影响。该行业致力于改善患者预后，这推动了具有更高疗效和安全性潜力的新型治疗方案的推出。在人们对干细胞疗法的认识和接受度不断提高的推动下，市场呈现出成长迹象。随着主要参与者寻求相互比较并获得竞争优势，市场竞争日益加剧。法规结构发挥着至关重要的作用，北美和欧洲严格的政策塑造着市场动态。这些法规确保了安全性和有效性，并影响市场进入和扩大策略。此外，旨在加速创新的合作与伙伴关係也丰富了市场。新兴市场在有利的法规环境和不断增长的医疗保健投资的推动下，提供了盈利的机会。随着生物技术的进步为变革性治疗方法铺平道路，未来前景一片光明。

主要趋势和驱动因素：

受再生医学进步和神经系统疾病盛行率上升的推动，用于治疗神经系统疾病的胎盘干细胞疗法市场正经历强劲增长。一个关键趋势是开发具有治疗潜在病因而非仅仅缓解症状潜力的创新干细胞治疗方法。这一转变吸引了来自公共和私营部门的大量投资，加速了研发进程。此外，随着监管机构日益认可干细胞疗法的潜力，一个更有利的法规结构正在形成。这加快了核准流程，鼓励更多公司进入市场。另一个驱动因素是医疗专业人员和患者对干细胞疗法的认知和接受度不断提高，这促进了治疗方法的广泛应用。此外，学术机构和生物技术公司之间的合作正在推动创新并拓展治疗产品线。新兴市场蕴藏着许多机会，这些市场的医疗基础设施正在快速改善，对先进疗法的需求旺盛。能够成功应对监管环境并证明疗效和安全性的公司将占据有利地位，最大限度地掌握这些机会。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 同种
    • 自有住房
  • 市场规模及预测：依产品划分
    • 冷冻保存的胎盘干细胞
    • 新鲜胎盘干细胞
  • 市场规模及预测：依服务划分
    • 干细胞库
    • 干细胞增殖
    • 干细胞分化
    • 咨询服务
  • 市场规模及预测：依技术划分
    • 细胞培养技术
    • 3D生物列印
    • 微流体技术
  • 市场规模及预测：依应用领域划分
    • 帕金森氏症
    • 阿兹海默症
    • 多发性硬化症
    • 中风
    • 脑性麻痹
    • 脊髓损伤
  • 市场规模及预测：依最终用户划分
    • 医院
    • 专科诊所
    • 研究所
    • 生物製药公司
  • 市场规模及预测：依製程划分
    • 分离
    • 增殖
    • 差异化
    • 冷冻保存
  • 市场规模及预测：依阶段划分
    • 临床前
    • 临床试验
    • 商业化
  • 市场规模及预测：按解决方案划分
    • 治疗方案
    • 诊断解决方案
  • 市场规模及预测：依治疗方法划分
    • 侵入性
    • 非侵入性

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Celularity
  • Pluristem Therapeutics
  • Re Neuron Group
  • Athersys
  • Brain Storm Cell Therapeutics
  • Neuro Generation
  • Stem Cells
  • Stempeutics Research
  • Fate Therapeutics
  • Neuralstem
  • Stem Bio Sys
  • Cytori Therapeutics
  • Brain Xell
  • Kadimastem
  • Promethera Biosciences
  • Medipost
  • Steminent Biotherapeutics
  • Cell Cure Neurosciences
  • Corestem
  • Biostage

第九章：关于我们

简介目录
Product Code: GIS26283

Placental Stem Cell Therapy for Neurological Disorders Market is anticipated to expand from $442.3 million in 2024 to $2,325.9 million by 2034, growing at a CAGR of approximately 31.7%. The Placental Stem Cell Therapy for Neurological Disorders Market encompasses treatments utilizing stem cells derived from placental tissue to address neurological conditions. This innovative approach leverages the regenerative potential of placental stem cells to repair damaged neural tissue and improve neurological function. The market is driven by increasing prevalence of neurological disorders, advancements in stem cell research, and growing investment in regenerative medicine. Key trends include personalized therapies, regulatory advancements, and strategic collaborations in research and development.

The Placental Stem Cell Therapy for Neurological Disorders Market is poised for significant growth, fueled by advancements in regenerative medicine and increasing prevalence of neurological conditions. The therapeutic applications segment leads performance, with Alzheimer's and Parkinson's disease therapies showing promising results. These therapies are becoming pivotal in addressing unmet medical needs. The research applications segment follows closely, driven by ongoing studies exploring the potential of placental stem cells in neurogenesis and neural repair. This segment's growth is supported by rising investments in clinical trials and research initiatives. Among sub-segments, autologous stem cell therapies are emerging as top performers due to their reduced risk of immune rejection and ethical considerations. Allogeneic therapies, being the second-highest performers, offer scalability and accessibility advantages, making them attractive for broader clinical applications. Innovations in stem cell harvesting and processing technologies are further enhancing the efficacy and safety profiles of these therapies, contributing to their growing adoption in the healthcare sector.

Market Segmentation
TypeAllogeneic, Autologous
ProductCryopreserved Placental Stem Cells, Fresh Placental Stem Cells
ServicesStem Cell Banking, Stem Cell Expansion, Stem Cell Differentiation, Consulting Services
TechnologyCell Culture Technology, 3D Bioprinting, Microfluidics
ApplicationParkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Stroke, Cerebral Palsy, Spinal Cord Injury
End UserHospitals, Specialty Clinics, Research Institutes, Biopharmaceutical Companies
ProcessIsolation, Expansion, Differentiation, Cryopreservation
StagePreclinical, Clinical Trials, Commercialization
SolutionsTherapeutic Solutions, Diagnostic Solutions
ModeInvasive, Non-Invasive

The Placental Stem Cell Therapy for Neurological Disorders Market is witnessing dynamic shifts in market share, pricing, and product innovation. The landscape is characterized by robust competition among leading biotechnology firms, each vying for dominance through strategic product launches. Pricing strategies are influenced by the advanced nature of therapies and the costs associated with research and development. This sector is marked by a focus on improving patient outcomes, driving the introduction of novel therapeutic solutions that promise enhanced efficacy and safety. The market is poised for growth, propelled by increasing awareness and acceptance of stem cell therapies. Competition in this market is intense, with key players benchmarking against each other to enhance their competitive edge. Regulatory frameworks play a pivotal role, with stringent policies in North America and Europe shaping market dynamics. These regulations ensure safety and efficacy, influencing market entry and expansion strategies. The market is further enriched by collaborations and partnerships aimed at accelerating innovation. Emerging markets present lucrative opportunities, driven by favorable regulatory environments and rising healthcare investments. The future landscape is promising, with advancements in biotechnology paving the way for transformative therapies.

Geographical Overview:

The placental stem cell therapy market for neurological disorders is witnessing dynamic growth across various regions. North America leads, driven by advanced healthcare infrastructure and increased research funding. The region's focus on innovative therapies and a high prevalence of neurological disorders bolster market expansion. Europe follows, with strong government support and a growing emphasis on regenerative medicine. The increasing incidence of neurological conditions in the aging population further propels market growth. In the Asia Pacific, rapid market expansion is evident, fueled by rising healthcare investments and a growing interest in stem cell research. Countries like China and India are emerging as significant players due to their large patient populations and supportive regulatory frameworks. Latin America and the Middle East & Africa are developing markets with untapped potential. Brazil and South Africa are witnessing increased investments in stem cell research, recognizing its potential to address unmet medical needs and drive economic growth.

Global tariffs and geopolitical risks are significantly influencing the Placental Stem Cell Therapy for Neurological Disorders Market. In Japan and South Korea, the focus is shifting towards enhancing domestic research capabilities and reducing dependency on imports, in response to trade tensions. China is aggressively pursuing self-sufficiency in biotechnological advancements, spurred by export restrictions and a drive for innovation. Taiwan, while a key player in biotech, faces geopolitical challenges that necessitate strategic alliances and diversification of supply chains. The parent market is experiencing robust growth globally, driven by advancements in regenerative medicine and increasing demand for innovative therapies. By 2035, the market is expected to expand significantly, contingent on geopolitical stability and resilient supply chains. Middle East conflicts could exacerbate global supply chain disruptions and elevate energy prices, impacting production costs and timelines.

Key Trends and Drivers:

The Placental Stem Cell Therapy for Neurological Disorders Market is experiencing robust growth, driven by advancements in regenerative medicine and increasing prevalence of neurological disorders. Key trends include the development of innovative stem cell therapies that offer potential cures rather than symptomatic treatments. This shift is attracting significant investment from both public and private sectors, accelerating research and development efforts. Furthermore, regulatory bodies are increasingly recognizing the potential of stem cell therapies, leading to more favorable regulatory frameworks. This is facilitating faster approval processes and encouraging more companies to enter the market. Another driver is the growing awareness and acceptance of stem cell therapies among healthcare professionals and patients, contributing to increased adoption. Additionally, collaborations between academic institutions and biotech companies are fostering innovation and expanding the therapeutic pipeline. Opportunities abound in emerging markets where healthcare infrastructure is rapidly improving, and there is a high demand for advanced medical treatments. Companies that can navigate regulatory landscapes and demonstrate efficacy and safety are well-positioned to capitalize on these opportunities.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Allogeneic
    • 4.1.2 Autologous
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cryopreserved Placental Stem Cells
    • 4.2.2 Fresh Placental Stem Cells
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Stem Cell Banking
    • 4.3.2 Stem Cell Expansion
    • 4.3.3 Stem Cell Differentiation
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell Culture Technology
    • 4.4.2 3D Bioprinting
    • 4.4.3 Microfluidics
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Parkinson's Disease
    • 4.5.2 Alzheimer's Disease
    • 4.5.3 Multiple Sclerosis
    • 4.5.4 Stroke
    • 4.5.5 Cerebral Palsy
    • 4.5.6 Spinal Cord Injury
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Specialty Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Biopharmaceutical Companies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Isolation
    • 4.7.2 Expansion
    • 4.7.3 Differentiation
    • 4.7.4 Cryopreservation
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Therapeutic Solutions
    • 4.9.2 Diagnostic Solutions
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Invasive
    • 4.10.2 Non-Invasive

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Celularity
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Pluristem Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Re Neuron Group
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Athersys
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Brain Storm Cell Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Neuro Generation
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Stem Cells
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Stempeutics Research
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Fate Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Neuralstem
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Stem Bio Sys
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cytori Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Brain Xell
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Kadimastem
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Promethera Biosciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Medipost
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Steminent Biotherapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cell Cure Neurosciences
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Corestem
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Biostage
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us